S&P 500   3,920.63 (+1.01%)
DOW   31,930.97 (+1.25%)
QQQ   321.77 (+0.09%)
AAPL   124.26 (-1.27%)
MSFT   232.83 (-0.19%)
FB   264.53 (-0.50%)
GOOGL   2,070.04 (+0.48%)
AMZN   3,151.69 (-1.34%)
TSLA   728.23 (+4.21%)
NVDA   569.60 (+0.69%)
BABA   249.83 (-1.16%)
CGC   35.59 (+0.79%)
GE   13.16 (+4.53%)
MU   90.77 (+2.88%)
NIO   51.09 (+4.03%)
AMD   85.79 (+1.24%)
T   29.36 (+0.62%)
F   12.00 (+3.27%)
ACB   11.39 (+1.61%)
DIS   199.05 (+0.99%)
BA   226.84 (+6.94%)
NFLX   550.54 (+0.80%)
BAC   36.21 (+1.94%)
S&P 500   3,920.63 (+1.01%)
DOW   31,930.97 (+1.25%)
QQQ   321.77 (+0.09%)
AAPL   124.26 (-1.27%)
MSFT   232.83 (-0.19%)
FB   264.53 (-0.50%)
GOOGL   2,070.04 (+0.48%)
AMZN   3,151.69 (-1.34%)
TSLA   728.23 (+4.21%)
NVDA   569.60 (+0.69%)
BABA   249.83 (-1.16%)
CGC   35.59 (+0.79%)
GE   13.16 (+4.53%)
MU   90.77 (+2.88%)
NIO   51.09 (+4.03%)
AMD   85.79 (+1.24%)
T   29.36 (+0.62%)
F   12.00 (+3.27%)
ACB   11.39 (+1.61%)
DIS   199.05 (+0.99%)
BA   226.84 (+6.94%)
NFLX   550.54 (+0.80%)
BAC   36.21 (+1.94%)
S&P 500   3,920.63 (+1.01%)
DOW   31,930.97 (+1.25%)
QQQ   321.77 (+0.09%)
AAPL   124.26 (-1.27%)
MSFT   232.83 (-0.19%)
FB   264.53 (-0.50%)
GOOGL   2,070.04 (+0.48%)
AMZN   3,151.69 (-1.34%)
TSLA   728.23 (+4.21%)
NVDA   569.60 (+0.69%)
BABA   249.83 (-1.16%)
CGC   35.59 (+0.79%)
GE   13.16 (+4.53%)
MU   90.77 (+2.88%)
NIO   51.09 (+4.03%)
AMD   85.79 (+1.24%)
T   29.36 (+0.62%)
F   12.00 (+3.27%)
ACB   11.39 (+1.61%)
DIS   199.05 (+0.99%)
BA   226.84 (+6.94%)
NFLX   550.54 (+0.80%)
BAC   36.21 (+1.94%)
S&P 500   3,920.63 (+1.01%)
DOW   31,930.97 (+1.25%)
QQQ   321.77 (+0.09%)
AAPL   124.26 (-1.27%)
MSFT   232.83 (-0.19%)
FB   264.53 (-0.50%)
GOOGL   2,070.04 (+0.48%)
AMZN   3,151.69 (-1.34%)
TSLA   728.23 (+4.21%)
NVDA   569.60 (+0.69%)
BABA   249.83 (-1.16%)
CGC   35.59 (+0.79%)
GE   13.16 (+4.53%)
MU   90.77 (+2.88%)
NIO   51.09 (+4.03%)
AMD   85.79 (+1.24%)
T   29.36 (+0.62%)
F   12.00 (+3.27%)
ACB   11.39 (+1.61%)
DIS   199.05 (+0.99%)
BA   226.84 (+6.94%)
NFLX   550.54 (+0.80%)
BAC   36.21 (+1.94%)
Log in
NASDAQ:ABUS

Arbutus Biopharma Short Interest Ratio and Short Volume

$3.98
+0.15 (+3.92 %)
(As of 02/24/2021 01:13 PM ET)
Add
Compare
Today's Range
$3.91
Now: $3.98
$4.05
50-Day Range
$3.55
MA: $4.09
$4.84
52-Week Range
$0.88
Now: $3.98
$9.02
Volume59,342 shs
Average Volume3.20 million shs
Market Capitalization$337.94 million
P/E RatioN/A
Dividend YieldN/A
Beta3.15

Short Interest

Arbutus Biopharma (NASDAQ:ABUS) Short Interest Data

Current Short Volume:3,190,000 shares
Previous Short Volume:4,050,000 shares
Change Vs. Previous Month:-21.23%
Dollar Volume Sold Short:$14.13 million
Short Interest Ratio / Days to Cover:1.0
Last Record Date:January, 29 2021
Outstanding Shares:56,850,000 shares
Percentage of Shares Shorted:3.76%
Today's Trading Volume:59,342 shares
Average Trading Volume:3,195,567 shares
Today's Volume Vs. Average:-98.14%


Arbutus Biopharma (NASDAQ:ABUS) Short Interest History

Report DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date
1/29/20213,190,000 shares $14.13 million -21.2%N/A0.8 $4.43
1/15/20214,050,000 shares $14.86 million -16.0%N/A1.2 $3.67
12/31/20202,950,000 shares $12.74 million +37.9%N/A1 $4.32
12/15/20202,950,000 shares $10.47 million +37.9%N/A1 $3.55
11/30/20202,140,000 shares $9.31 million -2.3%N/A1.1 $4.35
11/15/20202,190,000 shares $9.92 million -17.7%N/A1.3 $4.53
10/30/20202,660,000 shares $9.66 million +32.3%N/A1.4 $3.63
10/15/20202,010,000 shares $5.81 million -36.2%N/A0.6 $2.89
9/30/20203,150,000 shares $10.30 million +4.7%N/A0.3 $3.27
9/15/20203,010,000 shares $9.27 million +14.9%N/A0.3 $3.08
8/31/20202,620,000 shares $6.37 million -0.8%N/A0.3 $2.43
8/14/20202,640,000 shares $7.29 million +34.0%N/A0.3 $2.76
7/31/20201,970,000 shares $6.80 million +157.5%3.9%0.2 $3.45
7/15/2020765,100 shares $2.92 million +19.3%1.6%0.1 $3.81
6/30/2020641,200 shares $3.18 million +11.8%1.3%0.6 $4.96
6/15/2020573,400 shares $1.05 million +1.4%1.2%0.5 $1.83
5/29/2020565,300 shares $1.17 million +31.5%1.1%0.5 $2.07
5/15/2020429,900 shares $932,883.00 +4.9%0.9%0.4 $2.17
4/30/2020409,800 shares $909,756.00 +18.8%0.9%0.5 $2.22
4/15/2020345,000 shares $496,800.00 -34.6%0.8%0.4 $1.44
3/31/2020527,700 shares $638,517.00 -6.6%1.2%0.7 $1.21
3/13/2020564,800 shares $581,744.00 -4.8%1.5%1.8 $1.03
2/28/2020593,100 shares $978,615.00 +1.9%1.5%0.9 $1.65
2/14/2020581,900 shares $1.62 million -1.0%1.5%0.8 $2.78
1/31/2020587,600 shares $1.65 million -31.5%1.4%1 $2.80

Arbutus Biopharma (NASDAQ:ABUS) Short Interest FAQ

speech bubbles
speech bubbles











What is Arbutus Biopharma's current short interest?

Short interest is the volume of Arbutus Biopharma shares that have been sold short but have not yet been closed out or covered. As of January 29th, investors have sold 3,190,000 shares of ABUS short.

What is a good short interest ratio for Arbutus Biopharma?

The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. Arbutus Biopharma currently has a short interest ratio of 1.0.

Is Arbutus Biopharma's short interest increasing or decreasing?

Arbutus Biopharma saw a drop in short interest in the month of January. As of January 29th, there was short interest totaling 3,190,000 shares, a drop of 21.2% from the previous total of 4,050,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment.

How does Arbutus Biopharma's short interest compare to its competitors?

0.00% of Arbutus Biopharma's shares are currently sold short. Here is how the short interest of companies in the industry of "pharmaceutical preparations" compare to Arbutus Biopharma: Phathom Pharmaceuticals, Inc. (3.03%), Keros Therapeutics, Inc. (5.87%), Zogenix, Inc. (0.00%), Trillium Therapeutics Inc. (12.10%), MannKind Co. (0.00%), Pliant Therapeutics, Inc. (3.82%), Repare Therapeutics Inc. (2.40%), Annexon, Inc. (2.78%), Innoviva, Inc. (13.95%), and MacroGenics, Inc. (0.00%).

Which stocks are the most shorted right now?

As of the most recent reporting period, the following stocks had the largest short interest positions: Aon Plc ($5.34 billion), Charter Communications, Inc. ($5.03 billion), ViacomCBS Inc. ($4.99 billion), DuPont de Nemours, Inc. ($4.72 billion), Analog Devices, Inc. ($4.57 billion), Snap Inc. ($3.87 billion), Moderna, Inc. ($3.58 billion), Futu Holdings Limited ($2.75 billion), Snowflake Inc. ($2.43 billion), and Palantir Technologies Inc. ($2.18 billion). View all of the most shorted stocks.

What does it mean to sell short Arbutus Biopharma stock?

Short selling ABUS is an investing strategy that aims to generate trading profit from Arbutus Biopharma as its price is falling. Arbutus Biopharma's stock is trading up $0.15 today. To short Arbutus Biopharma stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that Arbutus Biopharma will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit.

How does a short squeeze work against Arbutus Biopharma?

A short squeeze for Arbutus Biopharma occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of ABUS, which in turn drives the price of the stock up even further.

How often is Arbutus Biopharma's short interest reported?

Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including ABUS, twice per month. The most recent reporting period available is January, 29 2021.



This page was last updated on 2/24/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.